Esterified estrogens / methyltestosterone Alternatives Compared
| Esterified estrogens / methyltestosterone | Veozah (fezolinetant) | Bijuva (estradiol / progesterone) |
|
|---|
| Esterified estrogens / methyltestosterone | Veozah (fezolinetant) | Bijuva (estradiol / progesterone) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Menopausal Disorders, Postmenopausal Symptoms, Hot Flashes. Esterified estrogens / methyltestosterone may also be used for purposes not listed in this medication guide. |
Prescription only
Veozah may be used to treat moderate to severe vasomotor symptoms of menopause such as hot flashes and night sweats. It is taken as an oral tablet, once daily but cannot be taken by women with... View more |
Prescription only
Prescribed for Perimenopausal Symptoms, Menopausal Disorders, Postmenopausal Symptoms, Hot Flashes. Bijuva may also be used for purposes not listed in this medication guide. |
Related suggestions Hot Flashes
Menopausal Disorders
|
|||||||||||||||||||||||
| More about Esterified estrogens / methyltestosterone | More about Veozah (fezolinetant) | More about Bijuva (estradiol / progesterone) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Esterified estrogens / methyltestosterone has an average rating of 9.1 out of 10 from a total of 36 ratings on Drugs.com. 89% of reviewers reported a positive effect, while 6% reported a negative effect. |
Veozah has an average rating of 7.7 out of 10 from a total of 45 ratings on Drugs.com. 56% of reviewers reported a positive effect, while 4% reported a negative effect. |
Bijuva has an average rating of 6.0 out of 10 from a total of 49 ratings on Drugs.com. 39% of reviewers reported a positive effect, while 27% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Esterified estrogens / methyltestosterone side effects |
View all Veozah side effects |
View all Bijuva side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
|
View all Veozah prices |
View all Bijuva prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Covaryx, Covaryx HS, EEMT, EEMT HS, Estratest F.S., Estratest H.S. |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
N/A |
9.6 hours |
26.47 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Moderate abuse potential
Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 274 drugs are known to interact with Esterified estrogens / methyltestosterone:
|
A total of 93 drugs are known to interact with Veozah:
|
A total of 416 drugs are known to interact with Bijuva:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
May 12, 2023 |
October 28, 2018 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.